D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

F. Bouet-toussaint, F. Cabillic, O. Toutirais, L. Gallo, M. et al., Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas, Cancer Immunol Immunother, vol.57, issue.4, pp.531-540, 2008.

A. Cordova, F. Toia, L. Mendola, C. Orlando, V. Meraviglia et al., Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas, PLoS One, vol.7, issue.11, p.49878, 2012.

M. Corvaisier, A. Moreau-aubry, E. Diez, J. Bennouna, J. F. Mosnier et al., V gamma 9V delta 2 T cell response to colon carcinoma cells, J Immunol, vol.175, issue.8, pp.5481-5489, 2005.

F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia et al., Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer, Cancer Res, vol.67, issue.15, pp.7450-7457, 2007.

M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian et al., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, vol.23, issue.10, pp.2346-57, 2005.

N. Kang, J. Zhou, T. Zhang, L. Wang, F. Lu et al., Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood, Cancer Biol Ther, vol.8, issue.16, pp.1540-1549, 2009.

V. Kunzmann, E. Bauer, J. Feurle, F. Weissinger, H. P. Tony et al., Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma, Blood, vol.96, issue.2, pp.384-92, 2000.

V. Kunzmann and M. Wilhelm, Anti-lymphoma effect of gammadelta T cells, Leuk Lymphoma, vol.46, issue.5, pp.671-80, 2005.

S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri et al., Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients, Clin Exp Immunol, vol.31, issue.2, pp.313-336, 2008.

M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger et al., Gammadelta T cells for immune therapy of patients with lymphoid malignancies, Blood, vol.102, issue.1, pp.200-206, 2003.

C. T. Morita, E. M. Beckman, J. F. Bukowski, Y. Tanaka, H. Band et al., Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells, Immunity, vol.3, issue.4, pp.90178-90185, 1995.

C. T. Morita, Y. Tanaka, B. R. Bloom, and M. B. Brenner, Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells, Res Immunol, vol.147, issue.5, pp.347-53, 1996.

W. K. Born, M. Aydintug, O. 'brien, and R. L. , Diversity of gammadelta T-cell antigens, Cell Mol Immunol, vol.10, issue.1, pp.13-20, 2013.

W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong et al., RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity, J Biol Chem, issue.26, pp.18922-18930, 2007.

V. Groh, A. Steinle, S. Bauer, and T. Spies, Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells, Science, issue.5357, pp.1737-1777, 1998.

H. Das, V. Groh, C. Kuijl, M. Sugita, C. T. Morita et al., MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function, Immunity, vol.15, issue.1, pp.168-174, 2001.

V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, issue.6908, pp.734-742, 2002.

P. Wrobel, H. Shojaei, B. Schittek, F. Gieseler, B. Wollenberg et al., Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition, Scand J Immunol, vol.66, issue.2-3, pp.320-328, 2007.

B. Rincon-orozco, V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle et al., Activation of V gamma 9V delta 2 T cells by NKG2D, J Immunol, vol.175, issue.4, pp.2144-51, 2005.

Y. Kong, W. Cao, X. Xi, C. Ma, L. Cui et al., The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D, Blood, vol.114, issue.2, pp.310-317, 2009.

J. Wu, V. Groh, and T. Spies, T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells, J Immunol, vol.169, issue.3, pp.1236-1276, 2002.

H. Shojaei, H. H. Oberg, M. Juricke, L. Marischen, M. Kunz et al., Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells, Cancer Res, vol.69, issue.22, pp.8710-8717, 2009.

V. Groh, S. Porcelli, M. Fabbi, L. L. Lanier, L. J. Picker et al., Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system, J Exp Med, vol.169, issue.4, pp.1277-94, 1989.

C. M. Parker, V. Groh, H. Band, S. A. Porcelli, C. Morita et al., Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire, J Exp Med, vol.171, issue.5, pp.1597-612, 1990.

S. Itohara, A. G. Farr, J. J. Lafaille, M. Bonneville, Y. Takagaki et al., Homing of a gamma delta thymocyte subset with homogeneous T-cell receptors to mucosal epithelia, Nature, vol.343, issue.6260, pp.754-761, 1990.

T. Goodman and L. Lefrancois, Intraepithelial lymphocytes. Anatomical site, not T cell receptor form, dictates phenotype and function, J Exp Med, vol.170, issue.5, pp.1569-81, 1989.

Y. Cai, X. Shen, C. Ding, C. Qi, K. Li et al., Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation, Immunity, vol.35, issue.4, pp.596-610, 2011.

E. E. Gray, K. Suzuki, and J. G. Cyster, Cutting edge: identification of a motile IL-17-producing gammadelta T cell population in the dermis, J Immunol, vol.186, issue.11, pp.6091-6096, 2011.

T. Hinz, D. Wesch, F. Halary, S. Marx, A. Choudhary et al., Identification of the complete expressed human TCR V gamma repertoire by flow cytometry, Int Immunol, vol.9, issue.8, pp.1065-72, 1997.

W. Holtmeier, M. Pfander, A. Hennemann, T. M. Zollner, R. Kaufmann et al., The TCR-delta repertoire in normal human skin is restricted and distinct from the TCR-delta repertoire in the peripheral blood, J Invest Dermatol, vol.116, issue.2, pp.275-80, 2001.

M. Bonneville, R. L. O'brien, and W. K. Born, Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity, Nat Rev Immunol, issue.7, pp.467-78, 2010.

A. C. Hayday, Cells: a right time and a right place for a conserved third way of protection, Annu Rev Immunol, vol.18, pp.975-1026, 2000.

A. Toulon, L. Breton, K. R. Taylor, M. Tenenhaus, D. Bhavsar et al., A role for human skin-resident T cells in wound healing, J Exp Med, vol.206, issue.4, pp.743-50, 2009.

A. S. Macleod and W. L. Havran, Functions of skin-resident gammadelta T cells, Cell Mol Life Sci, vol.68, issue.14, pp.662-668, 2009.

M. Hintz, A. Reichenberg, B. Altincicek, U. Bahr, R. M. Gschwind et al., Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli, FEBS Lett, vol.509, issue.2, pp.317-339, 2001.

B. Altincicek, J. Moll, N. Campos, G. Foerster, E. Beck et al., Cutting edge: human gamma delta T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis, J Immunol, vol.166, issue.6, pp.3655-3663, 2001.

H. J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori et al., Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells, J Exp Med, vol.197, issue.2, pp.163-171, 2003.

M. Bonneville and E. Scotet, Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors, Curr Opin Immunol, vol.18, issue.5, pp.539-585, 2006.

C. Riganti, M. Massaia, M. S. Davey, and M. Eberl, Human gammadelta T-cell responses in infection and immunotherapy: common mechanisms, common mediators?, Eur J Immunol, vol.42, issue.7, pp.1668-76, 2012.

V. Catros, O. Toutirais, F. Bouet, F. Cabillic, M. Desille et al.,

, Med Sci (Paris), issue.2, pp.185-91, 2010.

S. Buccheri, G. Guggino, N. Caccamo, L. Donni, P. Dieli et al., Efficacy and safety of gammadeltaT cell-based tumor immunotherapy: a meta-analysis, J Biol Regul Homeost Agents, vol.28, issue.1, pp.81-90, 2014.

A. Q. Gomes, D. S. Martins, and B. Silva-santos, Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application, Cancer Res, issue.24, pp.10024-10031, 2010.

T. R. Mosmann and S. Sad, The expanding universe of T-cell subsets: Th1, Th2 and more, Immunol Today, vol.17, issue.3, pp.80606-80608, 1996.

A. O'garra and N. Arai, The molecular basis of T helper 1 and T helper 2 cell differentiation, Trends Cell Biol, vol.10, issue.12, pp.542-50, 2000.

S. Romagnani, Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology, Int Arch Allergy Immunol, vol.98, issue.4, pp.279-85, 1992.

A. Sher and R. L. Coffman, Regulation of immunity to parasites by T cells and T cell-derived cytokines, Annu Rev Immunol, vol.10, pp.385-409, 1992.

M. R. Dunne, B. A. Mangan, L. Madrigal-estebas, and D. G. Doherty, Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vgamma9Vdelta2 T cells, Mediators Inflamm, p.704941, 2010.

V. E. Garcia, P. A. Sieling, J. Gong, P. F. Barnes, K. Uyemura et al., Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens, J Immunol, vol.159, issue.3, pp.1328-1363, 1997.

K. Tsukaguchi, B. De-lange, and W. H. Boom, Differential regulation of IFNgamma, TNF-alpha, and IL-10 production by CD4(+) alphabetaTCR+ T cells and vdelta2(+) gammadelta T cells in response to monocytes infected with Mycobacterium tuberculosis-H37Ra, Cell Immunol, vol.194, issue.1, pp.12-20, 1999.

A. Thedrez, C. Sabourin, J. Gertner, M. C. Devilder, S. Allain-maillet et al., Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue, Immunol Rev, vol.215, pp.123-158, 2007.

C. T. Morita, S. Verma, P. Aparicio, C. Martinez, H. Spits et al., Functionally distinct subsets of human gamma/delta T cells, Eur J Immunol, vol.21, issue.12, pp.2999-3007, 1991.

D. L. Gibbons, S. F. Haque, T. Silberzahn, K. Hamilton, C. Langford et al., Neonates harbour highly active gammadelta T cells with selective impairments in preterm infants, Eur J Immunol, vol.39, issue.7, pp.1794-806, 2009.

D. Wesch, A. Glatzel, and D. Kabelitz, Differentiation of resting human peripheral blood gamma delta T cells toward Th1-or Th2-phenotype, Cell Immunol, vol.212, issue.2, pp.110-117, 2001.

D. Vermijlen, P. Ellis, C. Langford, A. Klein, R. Engel et al., Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy, J Immunol, vol.178, issue.7, pp.4304-4318, 2007.

R. R. Bansal, C. R. Mackay, B. Moser, and M. Eberl, IL-21 enhances the potential of human gammadelta T cells to provide B-cell help, Eur J Immunol, vol.42, issue.1, pp.110-119, 2012.

N. Caccamo, M. Todaro, L. Manna, M. P. Sireci, G. Stassi et al., IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity, PLoS One, vol.7, issue.7, p.41940, 2012.

R. Casetti, C. Agrati, M. Wallace, A. Sacchi, F. Martini et al., Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation, J Immunol, vol.183, issue.6, pp.3574-3581, 2009.

N. Caccamo, L. Mendola, C. Orlando, V. Meraviglia, S. Todaro et al., Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells, Blood, vol.118, issue.1, pp.129-167, 2011.

K. J. Ness-schwickerath, J. C. Morita, and C. T. , Cytokine requirements for the differentiation and expansion of IL-17A-and IL-22-producing human Vgamma2Vdelta2 T cells, J Immunol, issue.12, pp.7268-80, 2010.

K. J. Ness-schwickerath and C. T. Morita, Regulation and function of IL-17A-and IL-22-producing gammadelta T cells, Cell Mol Life Sci, vol.68, issue.14, pp.2371-90, 2011.

P. Wu, D. Wu, C. Ni, J. Ye, W. Chen et al., GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer, Immunity, vol.40, issue.5, pp.785-800, 2014.

M. C. Devilder, S. Allain, C. Dousset, M. Bonneville, and E. Scotet, Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells, J Immunol, vol.183, issue.6, pp.3625-3658, 2009.

J. C. Ribot, S. T. Ribeiro, D. V. Correia, A. E. Sousa, and B. Silva-santos, Human gammadelta thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling, J Immunol, vol.192, issue.5, pp.2237-2280, 2014.

C. E. Sutton, S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle et al., Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, vol.31, issue.2, pp.331-372, 2009.

A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville et al., IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy, J Immunol, vol.182, issue.6, pp.3423-3454, 2009.

Y. Hu, Q. Cui, Y. Gu, L. Sheng, K. Wu et al., Decitabine facilitates the generation and immunosuppressive function of regulatory gammadeltaT cells derived from human peripheral blood mononuclear cells, Leukemia, vol.27, issue.7, pp.1580-1585, 2013.

F. Deknuydt, E. Scotet, and M. Bonneville, Modulation of inflammation through IL-17 production by gammadelta T cells: mandatory in the mouse, dispensable in humans?, Immunol Lett, vol.127, issue.1, pp.8-12, 2009.

M. L. Michel, D. J. Pang, S. F. Haque, A. J. Potocnik, D. J. Pennington et al., Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing gammadelta cells, Proc Natl Acad Sci U S A, vol.109, issue.43, pp.17549-54, 2012.

M. Brandes, K. Willimann, G. Bioley, N. Levy, M. Eberl et al., Crosspresenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses, Proc Natl Acad Sci U S A, vol.106, issue.7, pp.2307-2319, 2009.

M. Brandes, K. Willimann, and B. Moser, Professional antigen-presentation function by human gammadelta T Cells, Science, vol.309, issue.5732, pp.264-272, 2005.

N. Himoudi, D. A. Morgenstern, M. Yan, B. Vernay, L. Saraiva et al., Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells, J Immunol, vol.188, issue.4, pp.1708-1724, 2012.

F. Dieli, F. Poccia, M. Lipp, G. Sireci, N. Caccamo et al., Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites, J Exp Med, vol.198, issue.3, pp.391-398, 2003.

A. A. Alexander, A. Maniar, J. S. Cummings, A. M. Hebbeler, D. H. Schulze et al., Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma, Clin Cancer Res, vol.14, issue.13, pp.4232-4272, 2008.

D. F. Angelini, G. Borsellino, M. Poupot, A. Diamantini, R. Poupot et al., FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways, Blood, vol.104, issue.6, pp.1801-1808, 2004.

K. D. Jensen, X. Su, S. Shin, L. Li, S. Youssef et al., Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma, Immunity, vol.29, issue.1, pp.90-100, 2008.

J. C. Ribot, A. Pang, D. J. Neves, J. F. Peperzak, V. Roberts et al., CD27 is a thymic determinant of the balance between interferon-gamma-and interleukin 17-producing gammadelta T cell subsets, Nat Immunol, vol.10, issue.4, pp.427-463, 2009.

G. Turchinovich and A. C. Hayday, Skint-1 identifies a common molecular mechanism for the development of interferon-gamma-secreting versus interleukin-17-secreting gammadelta T cells, Immunity, vol.35, issue.1, pp.59-68, 2011.

G. Turchinovich and D. J. Pennington, T cell receptor signalling in gammadelta cell development: strength isn't everything, Trends Immunol, vol.32, issue.12, pp.567-73, 2011.

N. Schmolka, K. Serre, A. R. Grosso, M. Rei, D. J. Pennington et al., Epigenetic and transcriptional signatures of stable versus plastic differentiation of proinflammatory gammadelta T cell subsets, Nat Immunol, vol.14, issue.10, pp.1093-100, 2013.

R. Uchida, E. Ashihara, K. Sato, S. Kimura, J. Kuroda et al., Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface, Biochem Biophys Res Commun, vol.354, issue.2, pp.613-621, 2007.

S. R. Mattarollo, T. Kenna, M. Nieda, and A. J. Nicol, Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity, Cancer Immunol Immunother, vol.56, issue.8, pp.1285-97, 2007.

S. Dhar and S. V. Chiplunkar, Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vgamma9Vdelta2 T cells, Cancer Immun, vol.10, p.10, 2010.

M. D'asaro, L. Mendola, C. , D. Liberto, D. Orlando et al., V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells, J Immunol, issue.6, pp.3260-3268, 2010.

J. Mookerjee-basu, P. Vantourout, L. O. Martinez, B. Perret, X. Collet et al., F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells, J Immunol, issue.12, pp.6920-6928, 2010.

E. Scotet, L. O. Martinez, E. Grant, R. Barbaras, P. Jeno et al., Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I, Immunity, vol.22, issue.1, pp.71-80, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00139758

C. Harly, Y. Guillaume, S. Nedellec, C. M. Peigne, H. Monkkonen et al., Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset, Blood, vol.120, issue.11, pp.2269-79, 2012.

A. Sandstrom, C. M. Peigne, A. Leger, J. E. Crooks, F. Konczak et al., The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells, Immunity, vol.40, issue.4, pp.490-500, 2014.

C. R. Willcox, V. Pitard, S. Netzer, L. Couzi, M. Salim et al., Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor, Nat Immunol, vol.13, issue.9, pp.872-881, 2012.

T. Lanca, D. V. Correia, C. F. Moita, H. Raquel, A. Neves-costa et al., The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity, Blood, issue.12, pp.2407-2418, 2010.

D. C. Deniger, S. N. Maiti, T. Mi, K. C. Switzer, V. Ramachandran et al., Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies, Clin Cancer Res, vol.20, issue.22, pp.5708-5727, 2014.

V. Groh, R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein et al., Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB, Proc Natl Acad Sci U S A, issue.12, pp.6879-84, 1999.

L. S. Lamb, J. Bowersock, A. Dasgupta, G. Y. Gillespie, Y. Su et al., Engineered drug resistant gammadelta T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo-and immunotherapy, PLoS One, vol.8, issue.1, p.51805, 2013.

A. Poggi, C. Venturino, S. Catellani, M. Clavio, M. Miglino et al., Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid, Cancer Res, vol.64, issue.24, pp.9172-9181, 2004.

B. Xu, J. C. Pizarro, M. A. Holmes, C. Mcbeth, V. Groh et al., Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA, Proc Natl Acad Sci U S A, vol.108, issue.6, pp.2414-2423, 2011.

O. Toutirais, F. Cabillic, L. Friec, G. Salot, S. Loyer et al., DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells, Eur J Immunol, vol.39, issue.5, pp.1361-1369, 2009.

A. Knight, S. Mackinnon, and M. W. Lowdell, Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells, Cytotherapy, vol.14, issue.9, pp.1110-1118, 2012.

V. Lafont, J. Liautard, J. P. Liautard, and J. Favero, Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen, J Immunol, vol.166, issue.12, pp.7190-7199, 2001.

Z. Chen and M. S. Freedman, CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis, Clin Immunol, vol.128, issue.2, pp.219-246, 2008.

J. Gertner-dardenne, C. Bonnafous, C. Bezombes, A. H. Capietto, V. Scaglione et al., Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies, Blood, vol.113, pp.4875-84, 1920.

M. S. Braza, B. Klein, G. Fiol, and J. F. Rossi, Gammadelta T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody, Haematologica, vol.96, issue.3, pp.400-407, 2011.

H. Tokuyama, T. Hagi, S. R. Mattarollo, J. Morley, Q. Wang et al., V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs -rituximab and trastuzumab, Int J Cancer, vol.122, issue.11, pp.2526-2560, 2008.

A. H. Capietto, L. Martinet, and J. J. Fournie, Stimulated gammadelta T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer, J Immunol, vol.187, issue.2, pp.1031-1039, 2011.

A. Poggi, R. Carosio, D. Fenoglio, S. Brenci, G. Murdaca et al., Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat, Blood, vol.103, issue.6, pp.2205-2218, 2004.

C. Paget, M. T. Chow, H. Duret, S. R. Mattarollo, and M. J. Smyth, Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity, J Immunol, vol.188, issue.8, pp.3928-3967, 2012.

F. Halary, V. Pitard, D. Dlubek, R. Krzysiek, H. De-la-salle et al., Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells, J Exp Med, vol.201, issue.10, pp.1567-78, 2005.

Y. Lu, W. Yang, C. Qin, L. Zhang, J. Deng et al., Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis, J Immunol, vol.183, issue.10, pp.6413-6434, 2009.

J. E. Talmadge, P. L. Black, H. Tribble, R. Pennington, O. Bowersox et al., Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2, Drugs Exp Clin Res, vol.13, issue.6, pp.327-364, 1987.

F. J. Lejeune, D. Lienard, M. Matter, and C. Ruegg, Efficiency of recombinant human TNF in human cancer therapy, Cancer Immun, vol.6, p.6, 2006.

Y. Gao, W. Yang, M. Pan, E. Scully, M. Girardi et al., Gamma delta T cells provide an early source of interferon gamma in tumor immunity, J Exp Med, vol.198, issue.3, pp.433-475, 2003.

W. He, J. Hao, S. Dong, Y. Gao, J. Tao et al., Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin, J Immunol, issue.1, pp.126-159, 2010.

J. Riond, S. Rodriguez, M. L. Nicolau, T. Saati, and J. E. Gairin, In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth, Cancer Immun, vol.9, p.10, 2009.

A. Gaafar, M. D. Aljurf, A. Al-sulaiman, A. Iqniebi, P. S. Manogaran et al., Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients, Exp Hematol, vol.37, issue.7, pp.838-886, 2009.

C. Gu, L. Wu, and X. Li, IL-17 family: cytokines, receptors and signaling, Cytokine, vol.64, issue.2, pp.477-85, 2013.

Y. Ji and W. Zhang, Th17 cells: positive or negative role in tumor?, Cancer Immunol Immunother, issue.7, pp.979-87, 2010.

P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine et al., Tumorspecific Th17-polarized cells eradicate large established melanoma, Blood, vol.112, issue.2, pp.362-73, 2008.

G. Murugaiyan and B. Saha, Protumor vs antitumor functions of IL-17, J Immunol, vol.183, issue.7, pp.4169-75, 2009.

E. Maniati, R. Soper, and T. Hagemann, Up for mischief? IL-17/Th17 in the tumour microenvironment, Oncogene, issue.42, pp.5653-62, 2010.

D. Hannani, Y. Ma, T. Yamazaki, J. Dechanet-merville, G. Kroemer et al., Harnessing gammadelta T cells in anticancer immunotherapy, Trends Immunol, vol.33, issue.5, pp.199-206, 2012.

Y. Ma, L. Aymeric, C. Locher, S. R. Mattarollo, N. F. Delahaye et al., Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy, J Exp Med, vol.208, issue.3, pp.491-503, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00576679

M. Von-lilienfeld-toal, E. Sievers, V. Bodemuller, C. Mihailescu, A. Marten et al., Coculture with dendritic cells promotes proliferation but not cytotoxic activity of gamma/delta T cells, Immunol Lett, issue.1, pp.103-111, 2005.

F. Fiore, B. Castella, B. Nuschak, R. Bertieri, S. Mariani et al., Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on shortterm incubation with zoledronic acid, Blood, vol.110, issue.3, pp.921-928, 2007.

L. Conti, R. Casetti, M. Cardone, B. Varano, A. Martino et al., Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines, J Immunol, vol.174, issue.1, pp.252-60, 2005.

M. C. Devilder, S. Maillet, I. Bouyge-moreau, E. Donnadieu, M. Bonneville et al., Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation, J Immunol, vol.176, issue.3, pp.1386-93, 2006.

M. R. Dunne, L. Madrigal-estebas, L. M. Tobin, and D. G. Doherty, E)-4-hydroxy-3-methyl-but-2 enyl pyrophosphate-stimulated Vgamma9Vdelta2 T cells possess T helper type 1-promoting adjuvant activity for human monocytederived dendritic cells, Cancer Immunol Immunother, issue.7, p.59, 2010.

F. L. Schneiders, J. Prodohl, J. M. Ruben, T. O'toole, R. J. Scheper et al., CD1d-restricted antigen presentation by Vgamma9Vdelta2-T cells requires trogocytosis, Cancer Immunol Res, vol.2, issue.8, pp.732-772, 2014.

A. Maniar, X. Zhang, W. Lin, B. R. Gastman, C. D. Pauza et al., Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement, Blood, issue.10, pp.1726-1759, 2010.

A. A. Kuhl, N. N. Pawlowski, K. Grollich, M. Blessenohl, J. Westermann et al., Human peripheral gammadelta T cells possess regulatory potential, Immunology, vol.128, issue.4, pp.580-588, 2009.

Y. Drabsch and P. Ten-dijke, TGF-beta signalling and its role in cancer progression and metastasis, Cancer Metastasis Rev, vol.31, issue.3-4, pp.553-68, 2012.

W. C. Chen, Y. H. Lai, H. Y. Chen, H. R. Guo, I. J. Su et al., Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor, Histopathology, vol.63, issue.2, pp.225-258, 2013.

S. Cochaud, J. Giustiniani, C. Thomas, E. Laprevotte, C. Garbar et al., IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2, Sci Rep, vol.3, p.3456, 2013.

G. Peng, H. Y. Wang, W. Peng, Y. Kiniwa, K. H. Seo et al., Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway, Immunity, vol.27, issue.2, pp.334-382, 2007.

J. Ye, C. Ma, E. C. Hsueh, C. S. Eickhoff, Y. Zhang et al., Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence, J Immunol, vol.190, issue.5, pp.2403-2417, 2013.

C. Ma, Q. Zhang, J. Ye, F. Wang, Y. Zhang et al., Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer, J Immunol, vol.189, issue.10, pp.5029-5065, 2012.

F. Castiglione, A. Taddei, A. M. Buccoliero, F. Garbini, C. F. Gheri et al., TNM staging and T-cell receptor gamma expression in colon adenocarcinoma. Correlation with disease progression?, Tumori, vol.94, issue.3, pp.384-392, 2008.

N. Seo, Y. Tokura, F. Furukawa, and M. Takigawa, Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions, J Immunol, issue.8, pp.4138-4183, 1998.

N. Seo, Y. Tokura, M. Takigawa, and K. Egawa, Depletion of IL-10-and TGF-betaproducing regulatory gamma delta T cells by administering a daunomycinconjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells, J Immunol, vol.163, issue.1, pp.242-251, 1999.

J. Hao, S. Dong, S. Xia, W. He, H. Jia et al., Regulatory role of Vgamma1 gammadelta T cells in tumor immunity through IL-4 production, J Immunol, vol.187, issue.10, pp.4979-86, 2011.

M. Rei, N. Goncalves-sousa, T. Lanca, R. G. Thompson, S. Mensurado et al., Murine CD27(-) Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages, Proc Natl Acad Sci U S A, vol.111, issue.34, 2014.